Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma
European Journal of Cancer · 2026-10 · 247 · 117035
DOI: 10.1016/j.ejca.2026.117035 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026-10. Verfasst von Michael Günther und 19 weiteren Autor:innen. Beteiligte Einrichtung: Institute of General Pathology, Medical University Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Adipocytes, Biomarkers, Tumor. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Slovenian Research and Innovation Agency, Dr Rolf M Schwiete Foundation, Swiss National Science Foundation.
Abstract (Originalsprache)
BACKGROUND: Direct tumor-adipocyte contact (TAC), also referred to as Stroma AReactive Invasion Front Areas (SARIFA), is an emerging histomorphologic biomarker, defined by histologically visible direct tumor-adipocyte interaction. Its prognostic relevance in pancreatic ductal adenocarcinoma (PDAC) has not been investigated across independent cohorts. METHODS: In this international, real-world, multicenter study, TAC/SARIFA was assessed on 941 resected PDAC cases across five cohorts (Munich n = 400, Bern n = 215, Graz n = 111, Erlangen n = 101, TCGA n = 114). Clinicopathological correlations, survival analyses, and differential gene expression analyses were performed. RESULTS: TAC/SARIFA positivity was present in 53% of evaluable cases and showed substantial interobserver agreement across seven pathologists (mean Cohen's kappa: 0.71). TAC/SARIFA-positive tumors were associated with higher nodal (pN) stage, higher tumor grade, and older patient age (each p < 0.01). TAC/SARIFA positivity was significantly associated with reduced overall survival (pooled median OS: 14.1 vs. 28.0 months, p < 0.001) and remained an independent prognostic factor in multivariate analysis (pooled HR 1.84, 95% CI 1.59-2.14, p < 0.001). A significant interaction between TAC/SARIFA and sex was identified (p < 0.001), with a stronger prognostic effect in males (HR 2.46) than in females (HR 1.50). Adjuvant chemotherapy was associated with longer OS in both TAC/SARIFA subgroups, with a greater absolute survival difference in TAC/SARIFA-positive patients. Bulk transcriptomic profiling revealed upregulation of leptin (LEP) and the basal-like marker KRT14 in TAC/SARIFA-positive tumors. CONCLUSIONS: TAC/SARIFA is a robust, independent prognostic histomorphologic biomarker in PDAC with a sex-dependent effect. Its reproducible and quick assessment on routine H&E slides supports further investigation of its applicability for PDAC risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of General Pathology, Medical University Innsbruck, Innsbruck, Austria.
- Centre for Evolution and Cancer, Institute of Cancer Research, London, SM2 5NG, United Kingdom; Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
- Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
- Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.
- Division of General, Visceral and Transplant Surgery, Department of Surgery, Medical University of Graz, Graz, Austria.
- Institute of Pathology, Ludwig-Maximilians-Universität, Medical Faculty, Munich, Germany; Universitätsinstitut für Pathologie, Paracelsus Medizinische Universität, Klinikum Nürnberg, Nürnberg, Germany.
Förderung
- The Slovenian Research and Innovation Agency
- Dr Rolf M Schwiete Foundation
- Swiss National Science Foundation
Zitieren
APA
Günther, M., Bräutigam, K., Wartenberg, M., Arslan, M. D., Sucher, R., El-Mahrouk, M., Neumann, J., Grochowski, P., Wenning, A. S., Gloor, B., Dornieden, B., Grützmann, R., Pilarsky, C., Hartmann, A., Eckstein, M., Märkl, B., Matek, C., Skok, K., Ormanns, S., & Reitsam, N. G. (2026). Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. European Journal of Cancer, 247, 117035. https://doi.org/10.1016/j.ejca.2026.117035
Vancouver
Günther M, Bräutigam K, Wartenberg M, Arslan MD, Sucher R, El-Mahrouk M, et al. Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. European Journal of Cancer. 2026;247:117035. doi:10.1016/j.ejca.2026.117035
BibTeX
@article{Gnther2026,
author = {Günther, Michael and Bräutigam, Konstantin and Wartenberg, Martin and Arslan, Muhammed D and Sucher, Robert and El-Mahrouk, Mohamed and Neumann, Jens and Grochowski, Przemyslaw and Wenning, Anna S and Gloor, Beat and Dornieden, Berna and Grützmann, Robert and Pilarsky, Christian and Hartmann, Arndt and Eckstein, Markus and Märkl, Bruno and Matek, Christian and Skok, Kristijan and Ormanns, Steffen and Reitsam, Nic G},
title = {Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma},
journal = {European Journal of Cancer},
year = {2026},
volume = {247},
pages = {117035},
doi = {10.1016/j.ejca.2026.117035}
}
EUVIMED